Skip to main content

Featured

Daily Markets Update: TSX Hits 4-Month Low, Anthropic IPO Lifts Futures

  CANADIAN MONEY BRIEF Daily Markets Update Thursday, November 19, 2026  |  Wednesday’s closes, plus Thursday’s Asian session and U.S. futures The short version: A commodity rout hit Canada hardest. The S&P/TSX Composite Index lost 737.25 points, or 2.09%, to close at 34,578.05, its lowest finish in more than four months, as gold, copper and oil all fell sharply. On Wall Street, the Dow dropped 561 points and the S&P 500 notched a fifth straight loss, while the Nasdaq edged higher even after Nvidia’s post-earnings pop faded. Thursday opens on a brighter note: U.S. futures are up roughly 1% to 2% after Anthropic priced the largest IPO on record, ahead of its Nasdaq debut. Market Snapshot Index / Asset Level Change S&P/TSX Composite 34,578.05 ▼ -2.09% Dow Jones Industrial Average 50,198.17 ▼ -1.11% S&P 500 7,323.63 ▼ -0.23% Nasdaq Composite 24,429.88 ▲ +0.42% STOXX Europe 600 644.05 ▼ -1.03% Nikkei 225 (Thu.) 59,444.21 ▲ +0.71% Hang Seng (Thu.) 22,841.62 ▼ ...

article

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Comments